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Abstract 
Mood instability is a core clinical feature of affective and psychotic disorders.  In keeping with the 
Research Domain Criteria (RDoC) approach, it may be a useful construct for identifying biology that 
cuts across psychiatric categories.  We aimed to investigate the biological validity of a simple measure 
of mood instability and evaluate its genetic relationship with several psychiatric disorders, including 
major depressive disorder (MDD), bipolar disorder (BD), schizophrenia,  attention deficit hyperactivity 
disorder (ADHD), anxiety disorder and post-traumatic stress disorder (PTSD).  We conducted a 
genome-wide association study (GWAS) of mood instability in 53,525 cases and 60,443 controls from 
UK Biobank, identifying four independently-associated loci (on chromosomes eight, nine, 14 and 18), 
and a common single nucleotide polymorphism (SNP)-based heritability estimate of approximately 
8%.  We found a strong genetic correlation between mood instability and MDD (rg=0.60, SE=0.07, 
p=8.95x10-17) and a small but significant genetic correlation with both schizophrenia (rg=0.11, 
SE=0.04, p=0.01) and anxiety disorders (rg=0.28, SE=0.14, p=0.04), although no genetic correlation 
with BD, ADHD or PTSD.  Several genes at the associated loci may have a role in mood instability, 
including the deleted in colorectal cancer (DCC) gene, eukaryotic initiation factor 2B (eIF2B2), placental 
growth factor (PGF), and protein tyrosine phosphatase, receptor type D (PTPRD).  Strengths of this 
study include the very large sample size but our measure of mood instability may be limited by the 
use of a single question.  Overall, this work suggests a polygenic basis for mood instability.  This simple 
measure can be obtained in very large samples; our findings suggest that doing so may offer the 
opportunity to illuminate the fundamental biology of mood regulation.  
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Introduction 
Mood instability is a common clinical feature of affective and psychotic disorders, particularly major 
depressive disorder (MDD), bipolar disorder (BD) and schizophrenia1.  It may also be relatively 
common in the general population, estimated to affect around 13% of individuals2.  As a dimensional 
psychopathological trait, it is potentially a useful construct in line with the Research Domain Criteria 
(RDoC) approach3.  Mood instability may be of fundamental importance for understanding the 
pathophysiology of MDD and BD, as well as conditions such as borderline personality disorder, anxiety 
disorders, attention deficit hyperactivity disorder (ADHD) and psychosis4.  This trait is reported by 40-
60% of individuals with MDD5 and is recognised as part of the prodromal stage of BD6.  In established 
BD, it is a clinical feature which independently predicts poor functional outcome7.  Furthermore, 
general population twin studies suggest that an additive genetic influence accounts for 40% of the 
variance in measures of affect intensity and 25% of the variance in affective liability8. 
Population-based studies such as the Adult Psychiatric Morbidity Survey (APMS) have defined mood 
instability based on responses to a single question, while clinical studies have made use of more 
detailed rating scales4.  However, there is a lack of consensus about how best to measure and classify 
mood instability, and none of the currently available instruments adequately capture intensity, speed 
and frequency of affective change, or physiological and behavioural correlates.  A recent systematic 
review proposed that mood instability ďe defiŶed as ͞ƌapid osĐillations of intense affect, with a 
difficulty in regulating these oscillations or theiƌ ďehaǀiouƌal ĐoŶseƋueŶĐes͟9.  Applying this definition 
will require the future development and validation of a multidimensional assessment of mood 
instability, which is currently not available. 
Within the UK Biobank population cohort of over 0.5 million individuals10, the baseline assessment 
interview contained a question of relevance to mood instability, specifically: "Does your mood often 
go up and down?"  This is similar to the question for mood instability used within the APMS (͞Do you 
have a lot of sudden mood changes, suffered over the last several years͟Ϳ.  Hypothesizing that this 
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simple question taps into pathological mood instability, we predicted it would be more commonly 
endorsed by individuals within UK Biobank with MDD and BD, compared to individuals with no 
psychiatric disorder.  Moreover, under the hypothesis that this trait has cross-disorder 
pathophysiological relevance, we predicted that a genome-wide association study (GWAS) would 
identify shared genetic liability to mood instability and risk for psychiatric disorders in which 
disordered mood is a feature, including MDD, BD, schizophrenia, ADHD, anxiety disorder and PTSD.  
Given the size of the sample, we also aimed to identify loci associated with this measure of mood 
instability. 
 
Materials and methods 
Sample 
UK Biobank is a large cohort of more than 502,000 United Kingdom residents, aged between 40 and 
69 years10.  The aim of UK Biobank is to study the genetic, environmental and lifestyle factors that 
cause or prevent disease in middle and older age.  Baseline assessments occurred over a four-year 
period, from 2006 to 2010, across 22 United Kingdom (UK) centres.  These assessments were 
comprehensive and included social, cognitive, lifestyle, and physical health measures.  For the present 
study, we used the first genetic data release based on approximately one third of UK Biobank 
participants.  Aiming to maximise homogeneity, we restricted the sample to those who reported being 
of white UK ancestry (around 95% of the sample). 
UK Biobank obtained informed consent from all participants and this study was conducted under 
generic approval from the NHS National Research Ethics Service (approval letter dated 13 May 2016, 
Ref 16/NW/0274) and under UK Biobank approvals for application #ϲϱϱϯ ͞GeŶoŵe-wide association 
studies of ŵeŶtal health͟ ;PI DaŶiel “ŵith). 
Mood instability phenotype 
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As part of the baseline assessment, UK Biobank participants completed the 12 items of the neuroticism 
scale from the Eysenck Personality Questionnaire-Revised Short Form (EPQ-R-S)11.  One of these items 
assesses mood instability, namely: "Does your mood often go up and down?"  Participants responding 
͚Ǉes͛ to this ƋuestioŶ ǁeƌe ĐoŶsideƌed to ďe Đases of ŵood iŶstaďilitǇ aŶd those ƌespoŶdiŶg ͚Ŷo͛ ǁeƌe 
considered controls.  From the control sample, we excluded those who reported being on 
psychotropic medication, and those who reported a physician diagnosis of psychiatric disorder 
(including MDD, BD, anxiety/panic attacks, ͚nervous breakdown͛, schizophrenia and deliberate self-
harm/suicide attempt). 
After quality control steps (detailed below) aŶd eǆĐlusioŶs ;ϯ,ϲϳ9 paƌtiĐipaŶts ƌespoŶded ͚doŶ͛t kŶoǁ͛ 
aŶd Ϯϭϭ ƌespoŶded ͚pƌefeƌ Ŷot to saǇ͛Ϳ, the fiŶal sample for genetic analysis comprised 53,525 cases 
of mood instability and 60,443 controls.  Mood instability cases were younger than controls (mean 
age 55.8 years (SD=8.05) versus 57.7 years (SD=7.74); p<0.0001) and had a greater proportion of 
females (55.5% versus 49.6%; p<0.0001). 
Genotyping and imputation 
In June 2015, UK Biobank released the first set of genotypic data for 152,729 UK Biobank participants.  
Approximately 67% of this sample was genotyped using the Affymetrix UK Biobank Axiom array (Santa 
Clara, CA, USA) and the remaining 33% were genotyped using the Affymetrix UK BiLEVE Axiom array.  
These arrays have over 95% content in common.  Only autosomal data were available under the data 
release.  Data were pre-imputed by UK Biobank as fully described in the UK Biobank interim release 
documentation12.  Briefly, after removing genotyped SNPs that were outliers, or were multiallelic or 
of low frequency (minor allele frequency (MAF) <1%), phasing was performed using a modified version 
of SHAPEIT2 and imputation was carried out using IMPUTE2 algorithms, as implemented in a 
C++ platform for computational efficiency13, 14.  Imputation was based upon a merged reference panel 
of 87,696,888 biallelic variants on 12,570 haplotypes constituted from the 1000 Genomes Phase 3 and 
UK10K haplotype panels15.  Variants with MAF <0.001% were excluded from the imputed marker set.  
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Stringent quality control before release was applied by the Wellcome Trust Centre for Human 
Genetics, as described in UK Biobank documentation16.  
Statistical analyses 
Quality control and association analyses 
Before all analyses, further quality control measures were applied.  Individuals were removed based 
on UK Biobank genomic analysis exclusions (Biobank Data Dictionary item #22010), relatedness 
(#22012: genetic relatedness factor; a random member of each set of individuals with KING-estimated 
kinship coefficient >0.0442 was removed), gender mismatch (#22001: genetic sex), ancestry (#22006: 
ethnic grouping; principal component (PC) analysis identified probable Caucasians within those 
individuals who were self-identified as British and other individuals were removed from the analysis), 
and quality control failure in the UK BiLEVE study (#22050: UK BiLEVE Affymetrix quality control for 
samples and #22051: UK BiLEVE genotype quality control for samples).  A sample of 113,968 
individuals remained for further analyses.  Of these, 53,525 were classed as cases and 60,443 were 
classified as controls.  Genotype data were further filtered by removal of SNPs with Hardy–Weinberg 
equilibrium P<10−ϲ, with MAF <0.01, with imputation quality score <0.4 and with data on <90% of the 
sample after excluding genotype calls made with <90% posterior probability, after which 8,797,848 
variants were retained. 
Association analysis was conducted in PLINK17 using logistic regression under a model of additive allelic 
effects with sex, age, genotyping array and the first 8 PCs (Biobank Data Dictionary items #22009.01 
to #22009.08) as covariates.  Sex and age were included as covariates because cases and controls 
differed significantly on these measures.  Genetic PCs were included to control for hidden population 
structure within the sample, and the first 8 PCs, out of 15 available in the Biobank, were selected after 
visual inspection of each pair of PCs, taking forward only those that resulted in multiple clusters of 
individuals after excluding individuals self-reporting as being of non-white British ancestry (Biobank 
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Data Dictionary item #22006).  Overall, population structure had little impact on mood instability 
status.  The threshold for genome-wide significance was p<5.0x10-8. 
Heritability and genetic correlation between mood instability and psychiatric phenotypes 
We applied Linkage Disequilibrium Score Regression (LDSR)18 to the GWAS summary statistics to 
estimate SNP heritability (h2SNP).  Genetic correlations between mood instability and MDD, BD, 
schizophrenia, ADHD, anxiety disorder and PTSD were also evaluated using LDSR19 (with 
unconstrained intercept), a process that corrects for potential sample overlap without relying on the 
availability of individual genotypes 18.  For the MDD, BD, schizophrenia, ADHD, anxiety disorder and 
PTSD phenotypes, we used GWAS summary statistics provided by the Psychiatric Genomics 
Consortium (http://www.med.unc.edu/pgc/)20-25.  Note that for the purposes of these genetic 
correlation analyses we re-ran the GWAS of mood instability excluding from the cases those 9,865 
participants who reported being on psychotropic medication, or who self-reported psychiatric 
disoƌdeƌ ;MDD, BD, aŶǆietǇ/paŶiĐ attaĐks, ͚Ŷeƌǀous ďƌeakdoǁŶ͛, sĐhizophƌeŶia aŶd deliďeƌate self-
harm/suicide attempt).  This secondary GWAS output (rather than the primary GWAS reported below) 
was used for the genetic correlation calculations and for polygenic risk score analyses, the rationale 
being that this was a more conservative approach which would avoid genetic correlations between 
mood instability and MDD/BD/schizophrenia/ADHD/anxiety disorders/PTSD being driven by a subset 
of individuals with psychiatric disorder. 
Polygenic risk analysis of MDD, BD and schizophrenia as predictors of mood instability 
Profile risk scores (PRS) were created using the output of the PCG MDD 29 of 32 cohort GWAS 
(supplied by the MDD working group of the PGC,  http://www.med.unc.edu/pgc/pgc-workgroups), BD 
GWAS20 and schizophrenia GWAS21.  Five profile scores were created for each psychiatric phenotype 
using p-value cut offs of p<5x10-8, p<0.01, p<0.05, p<0.1, and p<0.5, with the exception of MDD for 
which there were no genome wide significant SNPs.  Ambiguous SNPs, indels (insertion/deletion 
mutations) and SNPs with an imputation score of less than 0.8 were removed.  LD was performed via 
PLINK on a random sample of 10,000 individuals using an r2>0.05 in a 250kb window.  SNPs were 
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clumped into sets and filtered, selecting the SNP with the lowest p-value from each set.  In the event 
that 2 or more SNPs from a set had the same p-value, the SNP with the largest beta coefficient was 
used.  PLINK was also used to calculate the profile scores to produce a per-allele weighted score with 
no mean imputation. 
Profile risk scores (PRS) modelling 
Only those subjects who were used for the genetic correlations analyses were used in the PRS 
analyses (that is, PRS analyses also excluded individuals in UK Biobank with psychiatric disorder).  
Modelling was performed in R (version 3.1.2) using the glm function.  Full sample and age-stratified 
analysis models were adjusted for age, sex, chip and PGCs 1-8, whereas sex-stratified analysis was 
not adjusted for sex. Scores where then split into deciles using the ntile function of the dplyr 
package.  Model Nagelkerke r2 was calculated using the fmsb package.   
 
Results 
Mood instability in MDD and BD within UK Biobank 
In previous work we have identified individuals within UK Biobank with a probable diagnosis of mood 
disorder, including cases of MDD (sub-divided into single episode MDD, recurrent moderate MDD and 
recurrent severe MDD) and BD, as well as non-mood disordered controls26.  These classifications were 
independent of response to the mood instability question or other questions from the EPQ-R-S.  For 
the group of participants who could be classified in this way, we assessed the proportion with mood 
instability within each mood disorder category.  All mood disorder groups had a significantly greater 
proportion of individuals with mood instability compared with the control group (Table 1), in which 
the prevalence was 35.3%.  This proportion was highest in the BD group (74.0%) followed by the three 
MDD groups (71.7% for recurrent severe MDD, 64.2% for recurrent moderate MDD and 43.7% for 
single episode MDD).  There were too few UK Biobank participants with a reliable classification of 
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schizophrenia, ADHD, anxiety disorder or PTSD to allow for an assessment of the prevalence of mood 
instability in these groups. 
GWAS of mood instability 
The mood instability GWAS results are summarised in Figure 1 (Manhattan plot), Figure 2 (QQ plot) 
and Table 2 (genome-wide significant loci associated with mood instability).  Regional plots are 
provided in Figures 3a-3d. 
Overall, the GWAS data showed modest deviation in the test statistics compared with the null (GC 
=1.13); this was negligible in the context of sample size (GC 1000=1.002). LDSR suggested that 
deviation from the null was due to a polygenic architecture in which h2SNP accounted for approximately 
8% of the population variance in mood instability (observed scale h2SNP=0.077 (SE 0.007)), rather than 
inflation due to unconstrained population structure (LD regression intercept=0.998 (SE 0.009)). 
We observed four independent genomic loci exhibiting genome-wide significant associations with 
mood instability (Figure 1, Table 2 and Figures 3a-d), on chromosome eight (index SNP rs7829975; 
CLDN23 and MFHAS1), chromosome nine (index SNP rs10959826; PTPRD), chromosome 14 (index SNP 
rs397852991; LTBP2, AREL1, FCF1, YLPM1, PROX2, DLST, RPS6KL1, PGF, EIF2B2 and MLH3) and 
chromosome 18 (index SNP rs8084280; DCC).  In total, there were 111 genome-wide significant SNPs 
across all loci.  Given the functional alleles that drive association signals in GWAS may not affect the 
nearest gene, we use the above gene names to provide a guide to location rather than to imply that 
altered function or expression of those genes are the sources of the association signals. 
We also repeated this GWAS for males and females separately (supplementary material Figure S1 and 
Figure S2) and for the sample stratified according to median age (age 58 and below, and age 59 and 
above; supplementary material Figure S3 and Figure S4).  No genome-wide significant loci were 
observed from these stratified analyses, possibly because of reduced power, apart from the retention 
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of a single genome-wide significant finding at rs8084280 on chromosome 18 (the DCC gene) for males 
only (supplementary material Figure S1). 
Within supplementary materials, we also present the results of the secondary GWAS of mood 
instability which excluded 9,865 participants with a psychiatric disorder (supplementary table S1).  
This GWAS was used to assess for genetic correlation between mood instability and MDD, BD, 
schizophrenia, ADHD, anxiety disorders and PTSD.  Supplementary table S1 shows that the risk allele 
frequencies (RAFs) of the index SNPs within the four genome-wide significant loci from the primary 
GWAS were very similar to the RAFs for these same SNPs within this secondary GWAS: for rs7829975 
the RAF was 0.516 versus 0.523; for rs10959826 it was 0.785 versus 0.789; for rs397852991 it was 
0.606 versus 0.673; and for rs8084280 it was 0.508 versus 0.514).  However, it should be noted that, 
perhaps due to a loss of power from excluding 9,865 individuals, only one of these four loci retained 
genome-wide significance (rs7829975 on chromosome 8). 
Genetic correlation of mood instability with MDD, schizophrenia, BD, ADHD, anxiety disorder and 
PTSD 
We identified strong genetic correlation between mood instability and MDD (rg=0.60, 
SE=0.07, p=8.95x10-17) and a smaller, but significant, correlation between mood instability and both 
schizophrenia (rg=0.11, SE=0.04, p=0.01) and anxiety disorders (rg= 0.28, SE=0.14, p=0.04) (Table 3).  
We did not find significant genetic overlap between mood instability and BD (rg=0.01, 
SE=0.05, p=0.27), ADHD (rg=0.14, SE=0.11, p=0.18) or PTSD (Rg=0.33, SE=0.17, p=0.06). 
Polygenic risk score analysis of MDD, BD and schizophrenia as predictors of mood instability 
Using the PRS approach, both MDD and schizophrenia had significant positive correlations with 
mood instability status (for MDD at p<0.5 PRS threshold: OR=1.029, 95%CI=1.02-1.033, r2=0.023, p= 
1.00x10-34 and for schizophrenia at p<0.1 PRS threshold: OR=1.009, 95%CI=1.005-1.014, r2=0.021, p= 
6.71x10-05) (supplementary material Table S2).  There was no evidence of an association between 
PRS for BD and mood instability.  This finding of a positive correlation between PRS for MDD and PRS 
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for schizophrenia with mood instability status (and no such correlation for BD PRS) was consistent 
across additional analyses stratified for sex and age (supplementary material Tables S3-S6). 
 
Discussion 
We have identified four independent loci associated with mood instability within a large population 
cohort, in what is to date the only GWAS of this phenotype.  We also identified a SNP-based heritability 
estimate for mood instability of approximately 8%, and a strong genetic correlation between mood 
instability and MDD, suggesting substantial genetic overlap between mood instability and vulnerability 
to MDD.  There was also a small but significant genetic correlation between mood instability and 
schizophrenia and between mood instability and anxiety disorders, but no significant genetic 
correlation with BD, ADHD or PTSD.  Polygenic risk score analyses found a positive correlation between 
both MDD and schizophrenia and mood instability status but this was not the case for BD. 
The strong genetic correlation between mood instability and MDD is of interest because it is consistent 
with the hypothesis that at least part of the pathophysiology of MDD might include a reduced capacity 
to effectively regulate affective states.  In support of this is evidence that individuals with MDD tend 
to have maladaptive responses to intense emotions, responding with worry, rumination and self-
criticism, which can then exacerbate negative emotional states27.  This maladaptive pattern of 
responses is also consistent with our finding of a small but significant genetic correlation between 
mood instability and both anxiety disorder and schizophrenia. 
The lack of genetic correlation between mood instability and BD was unexpected, given that mood 
instability is considered a core deficit in BD4 and was more common in our BD cases than MDD cases.  
Similarly, a genetic correlation between mood instability, ADHD and PTSD might have been 
anticipated.  This lack of correlation between mood instability and both BD/ADHD/PTSD is difficult to 
account for but might be explained by the relatively under-powered nature of the BD,  ADHD and PTSD 
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GWAS analyses, compared to the analyses used for MDD and schizophrenia.  It is worth noting that, 
although not significant, the magnitude of the genetic correlation between mood instability and ADHD 
was 0.14.  Similarly, the genetic correlation between mood instability and PTSD was not significant but 
had a magnitude of 0.33.It is well documented that MDD occurs more commonly in females than in 
males and it is possible that mood instability may be of greater relevance as a cross-cutting phenotype 
for women compared to men.  We therefore carried out a GWAS of mood instability for males and 
females separately (supplementary material Figure S1 and Figure S2).  These stratified analyses found 
no genome-wide significant loci for females and only one genome-wide significant locus for males (the 
previously identified locus on chromosome 18).  Although these analyses had reduced power, they 
suggest that there is no consistent difference in the genetic architecture of mood instability between 
the sexes.  Similarly, we carried out GWAS stratified by age, for those in the sample at or below the 
median age of 58 and for those above age 58 (supplementary material Figure S3 and Figure S4).  These 
age-stratified analyses did not identify any genome-wide significant loci. 
It is not possible to be certain which of the genes within associated loci are likely to be most relevant 
to the pathophysiology of mood instability but several genes of interest were identified.  For example, 
the lead SNP within the associated region on chromosome 18 lies in intron 9 of the DCC netrin 1 
receptor (originally named deleted in colorectal cancer; DCC) gene, with no other protein-coding genes 
for >500kb on either side (Figure 3d).  DCC is the receptor for the guidance cue netrin-1, which has a 
central role in the development of the nervous system, including (but not limited to) the organization 
and function of mesocorticolimbic dopamine systems28.  Recent studies have shown a range of human 
phenotypes associated with loss-of-function mutations in DCC, including agenesis of the corpus 
callosum, learning disabilities and mirror movements, all associated with a large-scale disruption of 
the development of commissural connectivity and lateralisation29, 30.  Manitt and colleagues have 
identified that DCC has a role in regulating the connectivity of the medial prefrontal cortex during 
adolescence and found that DCC expression was elevated in the brain tissue of antidepressant-free 
subjects who committed suicide31.  This suggests a possible role for DCC variants in increasing 
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predisposition to mood instability and mood disorders, as well as related psychopathological 
phenotypes. 
The associated region on chromosome 14 contains at least 10 candidate genes (Table 2 and Figure 3c).  
One of these is eukaryotic initiation factor 2B (EIF2B2), mutations in which are known to cause a range 
of clinically heterogeneous leukodystrophies32.  Reduced white matter integrity has been consistently 
associated with negative emotionality traits (such as harm avoidance, neuroticism and trait anxiety)33, 
as well as with MDD and BD34.  It is therefore possible that variation in EIF2B2 may have a role in mood 
instability. 
Another gene within the associated region on chromosome 14 is placental growth factor (PGF), a 
member of the angiogenic vascular endothelial growth factor (VEGF) family35, 36, which is expressed at 
high levels in the placenta and thyroid37.  PGF has a wide range of functions, including embryonic 
thyroid development38 and immune system function39, 40, as well as a role in atherosclerosis, 
angiogenesis in cancer, cutaneous delayed-type hypersensitivity, obesity, rheumatoid arthritis and 
pre-eclampsia39, 41-44.  PGF may be of interest because of the long-established association between 
thyroid dysfunction and both MDD and BD45, along with the recent observation that pre-eclampsia 
may be a marker for the subsequent development of mood disorders46.   
Also of interest is the finding that the gene for protein tyrosine phosphatase, receptor type D (PTPRD) 
lies within 1Mb of the associated region on chromosome 9 (Figure 3b).  PTPRD encodes a receptor-
type protein tyrosine phosphatase known to be expressed in brain and with an organising role at a 
variety of synapses, including those that play a role in synaptic plasticity47.  As such, it may have a role 
in a broad range of psychopathology. 
Two of the genomic loci associated with mood instability (on chromosomes eight and nine) overlap 
with loci found to be associated with neuroticism in a recent GWAS and meta-analysis which combined 
data from the UK Biobank cohort, the Generation Scotland cohort, and a cohort from the Queensland 
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Institute of Medical Research48.  The neuroticism study made use of scores on the 12-item EPQ-R-S 
questionnaire, of which one of the questions was the mood instability question used in the present 
study.  This overlap in findings suggests that mood instability is a key component of neuroticism as 
defined by the EPQ-R-S and that at least some of the gene variants implicated in mood instability are 
likely to contribute to the broader phenotype of neuroticism.  We did not assess for genetic correlation 
between mood instability and neuroticism using LDSR because both GWAS outputs were 
predominantly from the same UK Biobank sample.Strengths and limitations 
To the best of our knowledge, this is the first reported GWAS of mood instability.  It has enabled 
objective estimates of heritability and genetic correlation with important psychiatric disorders to be 
made for the first time.  In the future, genotyping data for the full UK Biobank sample (502,000 
participants) will be available.  This increased sample size may identify larger estimates of shared 
variance between mood instability and psychiatric disorders. 
Some important limitations of this work are acknowledged. The mood instability phenotype used was 
based on response to a single-item question ("Does your mood often go up and down?") which may 
be an imperfect measure of mood instability.  Approximately 44% of the whole UK Biobank cohort 
answered ͚yes͛ to this question, a much larger proportion than the 13% of participants classified as 
having mood instability within the UK APMS2.  This may be because the assessment of mood instability 
in the APMS was based on a slightly different question ;͞Do you have a lot of suddeŶ ŵood chaŶges͟) 
and because respondents had to additionally report that they ͞suffered this symptom over the last 
several years͟.  Clearly, a potential limitation of self-report is the possibility of responder bias and, 
further, a more complete and objectively-assessed measure of mood instability would have been 
preferable.  However, this was not available to us in the UK Biobank phenotype dataset and is unlikely 
to be feasible to collect within a population cohort of this size. 
Conclusions 
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Despite a recognition that mood instability is likely to be an important phenotype underpinning a 
range of psychiatric disorders - particularly mood disorders4 - there has to date been very little work 
on its neural correlates.  Early investigations tentatively suggest a role for altered function and/or 
connectivity of the amygdala49 but this is an area which is currently under-developed.  It is hoped that 
our findings will stimulate new research on mood instability, which may be a clinically useful and 
biologically valid trait that cuts across traditional diagnostic categories50. 
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Figure legends 
Figure 1.  Manhattan plot of GWAS of mood instability in UK Biobank (n=113,968). 
Figure 2.  QQ plot for UK Biobank mood instability GWAS results. 
Figures 3a-3d.  Regional plots of the four genome-wide significant mood instability loci. 
Figure 3a.  Chromosome 8 region 8.5MB-8.8MB 
Figure 3b.  Chromosome 9 region 10MB – 12MB 
Figure 3c.  Chromosome 14 region 75MB-75.5MB 
Figure 3d.  Chromosome 18 region 50.5MB-51MB 
Figure S1.  Manhattan plot of GWAS of mood instability in UK Biobank (males only). 
Figure S2.  Manhattan plot of GWAS of mood instability in UK Biobank (females only). 
Figure S3.  Manhattan plot of GWAS of mood instability in UK Biobank (age 58 and below). 
Figure S4.  Manhattan plot of GWAS of mood instability in UK Biobank (age 59 and above). 
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Table 1. Proportion of individuals with mood instability within mood disorder groups, 
compared to non-mood disordered controls. 
 Mood instability 
N (%) 
 
Pearson Chi-
squared 
P-value 
BD 
 
1,180 (74.0) 1.0x103 <0.001 
Recurrent MDD, severe 
 
6,303 (71.7) 4.5x103 <0.001 
Recurrent MDD, moderate 
 
9,509 (64.2) 4.4x103 <0.001 
Single episode MDD 
 
3,403 (43.7) 221.1 <0.001 
Non-mood disordered 
controls 
 
30,844 (35.3) - - 
BD bipolar disorder; MDD major depressive disorder 
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Table 2.  Genome-wide significant loci associated with mood instability in UK Biobank. 
Index SNP Chr Position 
Risk 
Allele/Other 
Allele 
RAF  Beta (SE) P-value Associated region Nearby Genes  
rs7829975 8 8,548,117 A/T 0.516 0.051 (0.0085) 1.8 x 10-9 8,548,117 – 8,704,330  CLDN23, MFHAS1 
rs10959826 9 11,459,410 G/A 0.785 0.060 (0.01) 7.7 x 10-9 11,459,410 – 11,701,596 PTPRD 
rs397852991 14 75,268,920 C/CA 0.606 0.053 (0.0088) 2.98 x 10-9 75,144,618 – 75,359,229 
LTBP2, AREL1, FCF1, YLPM1, 
PROX2, DLST, RPS6KL1, PGF, 
EIF2B2, MLH3 
rs8084280 18 50,726,749 T/A 0.508 0.050 (0.0085) 3.15 x 10-9 50,635,119 – 50,893,647 DCC 
Shown are LD-independent genome-wide significant SNP associations for mood instability (sorted by genomic position according to NCBI Build 37). Chromosome (Chr) and 
Position denote the location of the index SNP. RAF = risk allele frequency. Beta = logistic regression coefficient for allele1, SE = standard error for Beta. P-value = the 
probability of getting the derived test statistic under the null hypothesis. The final column indicates protein-coding genes at the associated loci (see regional plots in 
supplementary information) or, where there are no genes at the associated locus, the nearest gene if less than 1 MB from the locus. 
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Table 3. Genetic correlation between mood instability and MDD, schizophrenia, BD and ADHD. 
Phenotype Rg se z p h2 obs h2 obs se h2 int h2 int se Gcov int Gcov int se 
MDD 0.6 0.07 8.32 8.95 x10-17 0.11 0.01 0.99 0.008 -0.0019 0.006 
Schizophrenia 0.11 0.04 2.48 0.01 0.25 0.01 1.03 0.01 0.0008 0.007 
BD 0.01 0.05 0.27 0.27 0.12 0.01 1.02 0.008 0.0069 0.005 
PTSD 0.33 0.17 1.9 0.06 0.10 0.004 0.99 0.007 0.0004 0.005 
ADHD 0.14 0.11 1.35 0.18 0.4 0.15 1.01 0.01 0.0046 0.004 
Anxiety 
disorder 
0.28 0.14 2.04 0.04 0.06 0.03 1.00 0.01 0.01 0.005 
Rg = genetic correlation with mood instability; SE = standard error of the genetic correlation; Z = the test statistic; P= p-value. h2 obs = heritability on the observed scale; h2 
obs SE = the standard error of the heritability; h2 int = intercept of the heritability; h2 int SE = standard error of the heritability intercept; Gcov int = intercept of the genetic 
covariance; Gcov int SE = standard error of the genetic covariance intercept.  MDD = major depressive disorder; BD = bipolar disorder; PTSD = post-traumatic stress disorder; 
ADHD = attention deficit hyperactivity disorder. 
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Supplementary material 
  
Table S1.  Genome-wide significant loci associated with mood instability in UK Biobank (excluding 9,865 participants with psychiatric disorder) 
 
Index SNP Chr Position 
Risk 
Allele/Other 
Allele 
RAF Beta (SE) P-value 
rs7829975 8 8,548,117 A/T 0.523 0.052 (0.009) 5.32 x 10-9 
rs10959826 9 11,459,410 G/A 0.789 0.055 (0.01) 4.77 x 10-7 
rs397852991 14 75,268,920 C/CA 0.673 0.045 (0.009) 1.25 x 10-6 
rs8084280 18 50,726,749 T/A 0.514 0.047 (0.008) 1.35 x 10-7 
Shown are LD-independent genome-wide significant SNP associations for mood instability (sorted by genomic position according to NCBI Build 37). Chromosome (Chr) and 
Position denote the location of the index SNP. RAF = risk allele frequency. Beta = logistic regression coefficient for allele1, SE = standard error for Beta. P-value = the 
probability of getting the derived test statistic under the null hypothesis. The final column indicates protein-coding genes at the associated loci (see regional plots in 
supplementary information) or, where there are no genes at the associated locus, the nearest gene if less than 1 MB from the locus. 
 
Table S2 and Tables S3-“ϲ to folloǁ…. 
